Showing results (1-10 of 29) with videos related to
Sort By:
Pageof 3
European Journal of Pharmacology|October 18, 2000
Stress in schizophrenia: an integrative viewC C Gispen-de WiedNederlands Tijdschrift Voor Geneeskunde|June 19, 2003
[Schizophrenia and diabetes mellitus: not an improbable combination]D Cohen, C C Gispen-de WiedPsychopharmacology|May 24, 2000
Selective impairments in the stress response in schizophrenic patientsL M Jansen, C C Gispen-de Wied, R S KahnThe Journal of Nutrition, Health & Aging|March 21, 2009
The validity of biomarkers as surrogate endpoints in Alzheimer's disease by means of the Quantitative Surrogate Validation Level of Evidence Scheme (QSVLES)C C Gispen-de Wied, M Kritsidima, A J A ElferinkEuropean Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|November 3, 2005
Prevalence of diabetes mellitus in chronic schizophrenic inpatients in relation to long-term antipsychotic treatmentD Cohen, J J Dekker, J Peen, et al.Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|September 15, 2001
The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patientsF E Scheepers, C C Gispen-de Wied, H G Westenberg, et al.Clinical Chemistry|August 1, 1996
Determination of dexamethasone in salivaJ H Thijssen, C C Gispen-de Wied, G M van Heeswijk, et al.Psychoneuroendocrinology|January 1, 1987
The dexamethasone and cortisol suppression test in depression: beta-endorphin as a useful markerC C Gispen-de-Wied, H G Westenberg, J H Thijssen, et al.The American Journal of Psychiatry|April 3, 2001
Effect of clozapine on caudate nucleus volume in relation to symptoms of schizophreniaF E Scheepers, C C Gispen de Wied, H E Hulshoff Pol, et al.Drugs|July 29, 2017
Factors Contributing to the Efficacy-Effectiveness Gap in the Case of Orphan Drugs for Metabolic DiseasesY Schuller, C E M Hollak, C C Gispen-de Wied, et al.Pageof 3